Clinical predictors of response to immunotherapy in patients with extensive-stage small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Diverging paths: Identifying barriers to and increasing accessibility of a survivorship program in a socio-economically diverse community. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Imdelltra demonstrated superior overall survival and progression-free survival compared to standard chemotherapy in ES-SCLC patients post-platinum-based treatment. The DeLLphi-304 trial showed a ...

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer. During the CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York ...

Incremental dose to neurogenic niches correlated with reduced overall survival: SVZ HR 1.306/Gy and hippocampus HR 1.222/Gy, indicating independent adverse prognostic impact.

A 69-year-old Greeley woman had just hiked 8 miles in Sedona, Arizona, when she received a call that she had lung cancer. Despite her active lifestyle, a past of smoking crept up on her without any ...

Please provide your email address to receive an email when new articles are posted on . Non-lung secondary cancers can develop in survivors of lung cancer years after completion of definitive therapy.

CLEVELAND — Six years after doctors told him he had lung cancer, Tony Holland walks the halls of Cleveland Clinic Akron General with a unique perspective. The 65-year-old patient transporter doesn't ...

Research shows that cancer survivors can lower their risk of death with increased physical activity. Here's what Black cancer ...